Resonant Capital Advisors LLC Acquires Shares of 184,198 Caribou Biosciences, Inc. (NASDAQ:CRBU)

Resonant Capital Advisors LLC acquired a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 184,198 shares of the company’s stock, valued at approximately $1,055,000. Resonant Capital Advisors LLC owned about 0.21% of Caribou Biosciences at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Caribou Biosciences by 49.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,822,151 shares of the company’s stock valued at $18,270,000 after purchasing an additional 1,261,920 shares during the last quarter. Citigroup Inc. boosted its holdings in shares of Caribou Biosciences by 739.3% in the 3rd quarter. Citigroup Inc. now owns 221,166 shares of the company’s stock valued at $1,057,000 after buying an additional 194,816 shares in the last quarter. Barclays PLC boosted its holdings in shares of Caribou Biosciences by 1,296.0% in the 3rd quarter. Barclays PLC now owns 254,231 shares of the company’s stock valued at $1,215,000 after buying an additional 236,020 shares in the last quarter. Laurion Capital Management LP acquired a new position in shares of Caribou Biosciences in the 3rd quarter valued at $790,000. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Caribou Biosciences by 247.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,648,582 shares of the company’s stock valued at $12,660,000 after buying an additional 1,886,484 shares in the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their target price on shares of Caribou Biosciences from $23.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, March 19th.

Caribou Biosciences Trading Down 1.5 %

Shares of NASDAQ:CRBU opened at $3.85 on Friday. The firm has a fifty day moving average price of $5.82 and a 200 day moving average price of $5.44. Caribou Biosciences, Inc. has a 1-year low of $3.44 and a 1-year high of $8.59.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.17 million. Caribou Biosciences had a negative return on equity of 31.06% and a negative net margin of 296.05%. On average, research analysts forecast that Caribou Biosciences, Inc. will post -1.76 EPS for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.